SCHEMBL6753370

SCHEMBL6753370

O=C(Cl)Cc1ccc(N2C(=O)C=CC2=O)cc1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 15/20 0.60
FAAH O00519 6/20 0.60
NPSR1 Q6W5P4 3/20 0.52
HSP90AA1 P07900 2/20 0.52
TDP1 Q9NUW8 2/20 0.52
PKM P14618 1/20 0.52
MAPK1 P28482 1/20 0.52
DDAH1 O94760 1/20 0.52
ALDH1A1 P00352 2/20 0.46
HPGD P15428 2/20 0.46
HTT P42858 2/20 0.46
CACNA1B Q00975 1/20 0.46
APBA1 Q02410 1/20 0.46
CHRM1 P11229 1/20 0.44
LMNA P02545 1/20 0.42
MAPT P10636 1/20 0.42
BCHE P06276 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6755043 0.83 MGLL (0.62) MGLLFAAHNPSR1HSP90AA1TDP1
SCHEMBL24452258 0.81 MGLL (0.60) MGLLFAAHNPSR1HSP90AA1TDP1
SCHEMBL14750493 0.81 MGLL (0.61) MGLLFAAHNPSR1HSP90AA1TDP1
Hydrochloric Acid SCHEMBL6753371 0.81 MGLL (0.60) MGLLFAAHNPSR1HSP90AA1TDP1
Hydrazine SCHEMBL16908509 0.80 MGLL (0.58) MGLLFAAHNPSR1HSP90AA1TDP1
SCHEMBL12657331 0.80 MGLL (0.58) MGLLFAAHNPSR1HSP90AA1TDP1
SCHEMBL7443516 0.77 NR1H3 (0.59)
SCHEMBL6749977 0.77 AOC2 (0.59) MGLLFAAHNPSR1HSP90AA1TDP1
SCHEMBL4194796 0.77 CA2 (0.46) ALDH1A1HPGDHTTLMNA
SCHEMBL20495671 0.76 MGLL (0.69) MGLLFAAHNPSR1HSP90AA1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6709679-B2 CONSISTING OF NATIVE OR THIOLATED TRANSFERRIN OR ALBUMIN OR OF POLYETHYLENE GLYCOL WITH ATLEAST ONE MERCAPTAN, HYDROXY OR AMINE GROUP AND CYTOSTATIC COMPOUNDS DERIVED THROUGH MALEINIMIDE OR HYDROXYSUCCINIMIDE ESTER COMPOUNDS KRATZ FELIX (DE) 2004-03-23 US disclosed
US-20020019343-A1 Antineoplastic conjugates of transferrin, albumin and polyethylene glycol KRATZ FELIX (DE) 2002-02-14 US disclosed
US-6310039-B1 TUMOR-INHIBITING CONJUGATES OF PROTEINS AND POLYMERS CONSISTING OF A SUITABLE CARRIER SYSTEM AND CYTOSTATIC COMPOUNDS KRATZ FELIX (DE) 2001-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019343-A1 Antineoplastic conjugates of transferrin, albumin and polyethylene glycol TFRC, ALB, FOLR1 MGLL 3432/4885FAAH 1010/4885NPSR1 1238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.